TGF(β)-MIR200-MIG6 pathway and its use in the treatment of cancer as an indicator of resistance to EGFR inhibitors

Patent metadata

Field	Value
Publication number	US-10801071-B2
Application number	US-201515305750-A
Country	US
Kind code	B2
Filing date	Apr 22, 2015
Priority date	Apr 22, 2014
Publication date	Oct 13, 2020
Grant date	Oct 13, 2020

Abstract

The present invention provides methods for identifying the susceptibility of a cancer cell or population of cells to treatment with Epidermal Growth Factor (EGF) Tyrosine Kinase Inhibitors (TKIs), such as erlotinib. Methods for the in vitro diagnosis of the susceptibility of a tumor in a subject to treatment with TKIs and monitoring tumor susceptibility during treatment are also provided.

First claim

The invention claimed is:

1. A method for treating a subject having a cancer comprising:
a) isolating a RNA sample from a cancer cell or population of cells from the subject;
b) performing quantitative real-time PCR on the RNA from the sample of the cancer cell or population of cells using the PCR primers and probes specific for Mig6 mRNA, and for one or more microRNAs selected from the group consisting of: miR200a, miR200b, miR200c and miR205;
c) determining the ratio of the quantity of the Mig6 mRNA to the quantity of one or more microRNAs selected from the group consisting of: miR200a, miR200b, miR200c and miR205 in the sample of the cancer cell or population of cells and identifying the cancer of the subject as susceptible to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment when the ratio of Mig 6 mRNA to the quantity of one or more microRNAs is less than or equal to 0.05; and
d) administering to the subject an effective amount of at least one EGFR TKI.

2. The method of claim 1 , wherein the at least one EGFR TKI is selected from the group consisting of axitinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, niolinib, pazopanib, sorafenib, and sunitinib.

3. The method of claim 2 , wherein the method further comprises administering to the subject an effective amount of at least one additional chemotherapeutic agent which is not a EGFR TKI.

4. The method of claim 1 , wherein the method further comprises repeating steps a) to c) during treatment of the subject.

5. A method for treating a subject having a cancer comprising:
a) isolating a RNA sample from a cancer cell or population of cells from the subject;
b) performing quantitative real-time PCR on the RNA from the sample of the cancer cell or population of cells using the PCR primers and probes specific for Mig6 mRNA, and for one or more microRNAs selected from the group consisting of: miR200a, miR200b, miR200c and miR205;
c) determining the ratio of the quantity of the Mig6 mRNA to the quantity of one or more microRNAs selected from the group consisting of: miR200a, miR200b, miR200c and miR205 in the sample of the cancer cell or population of cells and identifying the cancer of the subject as susceptible to TGFβinhibitor treatment when the ratio of Mig6 mRNA to the quantity of one or more microRNAs is greater than 0.05; and
d) administering to the subject an effective amount of at least one TGFβinhibitor.

6. The method of claim 5 , wherein the TGFβinhibitor is selected from the group consisting of SB-431542, A-83-01, D-4476, LY-364947, GW-788388, SB-505124, or TGFβRII/Fc.

7. The method of claim 5 , wherein the method further comprises repeating steps a) to c) during treatment of the subject.

Assignees

• Univ Johns Hopkins

Inventors

• Sidransky David
• Izumchenko Eugene

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title